Compare Google Inc (GOOG) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Google Inc vs Merck & Co., Inc. — how do they compare? Google Inc trades at $349.65 (market cap $4.24T), while Merck & Co., Inc. trades at $145.09 (market cap $351.28B). The key difference: Google Inc is far larger — about 12.1× Merck & Co., Inc.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Google Inc for 137 Days and Merck & Co., Inc. for 98 Days on average.
| GOOG | MRK | |
|---|---|---|
Market Cap | $4.24T | $351.28B |
Volume | 13,937,902 | 7,969,665 |
Sector | Media | Health |
52-Week High | $399.06 | $156.43 |
52-Week Low | $237.49 | $82.49 |
Typical Hold Time | 137 Days | 98 Days |
Enterprise Value | $4.13T | $398.04B |
Dividend Yield | 0.26% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOG) trades at $347.37, up 0.81% with strong bullish technical signals. The company demonstrates exceptional fundamental strength with 2025 revenue of $402.84B and net income of $132.17B, maintaining robust profitability margins. Recent earnings beats and aggressive AI investments highlight growth momentum, though capital expenditure spikes have raised free cash flow concerns. Analyst consensus remains overwhelmingly positive with 87% buy ratings and a $435.24 price target.
Alphabet presents a compelling growth story with dominant market positioning and AI leadership, though investors face risks from regulatory scrutiny, intense competition, and significant capital expenditure requirements. The stock's current valuation appears reasonable relative to growth prospects, with technical indicators supporting near-term upside potential toward resistance levels around $350-352.
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Google Inc
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
